Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The study assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced tumors. Objective responses were observed in 30 (29%) of 102 patients in the tT MB-high group and 43 (6%) of 688 in the non-MB- high group.
